文献速递甲状腺疾病

重组人促甲状腺激素改善分化型甲状腺癌甲状腺切除患者的内皮冠状动脉血流储备

Recombinant Human Thyrotropin Improves Endothelial Coronary Flow Reserve in Thyroidectomized Patients with Differentiated Thyroid Cancer.
PubMed 文献 · Thyroid · 2016-10-14

研究纳入10例无心血管危险因素的分化型甲状腺癌全甲状腺切除术后患者,在左甲状腺素维持促甲状腺激素(TSH)于参考范围期间,于第二次重组人促甲状腺激素(rhTSH)注射前及注射后24小时行冷加压试验(CPT)评估冠状动脉血流储备(CFR)。结果显示rhTSH后CPT后血流速度及CFR较基线升高,静息血流速度无显著差异,提示rhTSH可能改善CFR。

要点

  • rhTSH后CFR较基线升高(1.32±0.2 vs 1.53±0.2,p<0.01)。
  • rhTSH后CPT后冠状动脉血流峰值速度较基线升高(29.3±6.8 vs 34.4±10.9,p<0.05)。
  • 静息冠状动脉血流峰值速度rhTSH前后无显著差异(22.3±6 vs 23.2±8.7,p=0.66)。

核心结论

  • 在无心血管危险因素的分化型甲状腺癌全甲状腺切除术后患者中,rhTSH给药可能在非药物应激源CPT后改善CFR。
  • rhTSH后冠状动脉血流增加提示TSH可能对冠状动脉内皮发挥保护作用。

研究设计与样本

  • 研究人群为3例男性和7例女性(平均年龄32.6±8岁),均因分化型甲状腺癌行全甲状腺切除术。
  • 所有患者均接受左甲状腺素治疗以维持TSH在参考范围内。
  • 无患者肥胖,或无高血压、糖尿病或血脂异常。
  • 患者在第二次rhTSH注射前及注射后24小时行标准超声多普勒检查,通过冷加压试验评估左前降支远端冠状动脉血流储备。

主要发现

  • 所有患者左心室形态及收缩和舒张功能均正常。
  • 甲状腺激素、甲状腺球蛋白及抗甲状腺球蛋白抗体水平在rhTSH治疗前后无显著差异,而rhTSH给药后TSH水平升高。
  • 血压和心率未受rhTSH影响。
  • 静息冠状动脉血流峰值速度在基线与rhTSH后24小时无显著差异(22.3±6 vs 23.2±8.7;p=0.66)。
  • CPT后血流速度在rhTSH后较基线升高(29.3±6.8 vs 34.4±10.9;p<0.05),CFR在rhTSH后较基线升高(1.32±0.2 vs 1.53±0.2;p<0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of thyrotropin (TSH) on the cardiovascular system has been poorly investigated. It is unknown whether the changes in the vasculature associated with thyroid diseases result from altered thyroid hormone action or whether they are a consequence of a direct effect of TSH on endothelial cells. The present study was designed to evaluate the endothelial response of coronary flow to TSH in patients with differentiated thyroid cancer (DTC) without cardiovascular risk factors. METHODS: The study population consisted of three men and seven women (Mage = 32.6 ± 8 years) who underwent total thyroidectomy for DTC. All were receiving therapy with L-thyroxine to maintain TSH within the reference range. No patient was obese, or had hypertension, diabetes, or dyslipidemia. Patients underwent standard echo-Doppler examination with evaluation of the coronary flow reserve (CFR) of the distal left anterior descending artery obtained by cold pressure test (CPT) before and 24 h after the second recombinant human TSH (rhTSH) injection. RESULTS: Left ventricular morphology and systolic and diastolic function were normal in all patients. Levels of thyroid hormones and thyroglobulin and antithyroglobulin antibodies did not differ significantly pre- versus post-rhTSH treatment, whereas TSH levels were higher after rhTSH administration. Blood pressure and heart rate were not affected by rhTSH. Coronary flow peak velocity at rest (22.3 ± 6 vs 23.2 ± 8.7; p = 0.66) did not differ between baseline and 24 h after rhTSH, while post-CPT velocity (29.3 ± 6.8 vs 34.4 ± 10.9; p < 0.05) and the CFR were higher after rhTSH administration (1.32 ± 0.2 vs. 1.53 ± 0.2; p < 0.01). CONCLUSIONS: rhTSH administration may improve the CFR after the non-pharmacological stressor CPT in DTC patients. The increase of coronary blood flow after rhTSH suggests that TSH may exert a protective effect on the coronary endothelium.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Ippolito S, Ippolito R, Peirce C, et al. Recombinant Human Thyrotropin Improves Endothelial Coronary Flow Reserve in Thyroidectomized Patients with Differentiated Thyroid Cancer. Thyroid. 2016. PMID: 27558484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。